Full Research Professor at the Department of Immunology of the National School of Biological Sciences (ENCB) of the National Polytechnic Institute (IPN) and Lecturer of Immunology at the Faculty of Chemistry of the National Autonomous University of Mexico (UNAM). She graduated as Pharmacist-Chemist Biologist at the Faculty of Chemistry of UNAM, and earned her Master and PhD degrees in Immunology Sciences from the ENCB of the IPN. Dr. Perez Tapia is specialist in innovation, development, assessment and regulatory affairs of biologics and biotechnological products for human use. She is an innovative researcher, being representative of the new generation of entrepreneurial scientists in Mexico, selected by the Forbes magazine as one of the most influential women in Mexico in 2020 and 2021.

 

So far, Dr. Perez Tapia has published 109 articles in peer-reviewed journals, plus 7 book chapters, and has directed more than 60 theses (Bachelors, Masters and PhD). She owns a patent granted in 40 countries including: México, USA, Peru, Colombia, Canada and the European Union, and other 9 patent submissions ongoing. She is member of the National System of Researchers in Mexico, SNI (level 2 of 3) and is awarded as Research Professor under the institutional program EDI of IPN (level 9 of 9).

 

Dr. Perez Tapia is the Director of the Unit for Development and Research in Bioprocesses (UDIBI), which is the core center of research and technological innovation at UDIMEB-IPN. UDIBI was founded in 2010 to promote the research and development of leukocyte dialyzable extracts. Nowadays UDIBI is part of the National Laboratories network of CONACYT and provides specialized services to the academia and the local and international biotechnology industries. These services include analytical, immunological and biological characterization tests, preclinical studies, and during the recent 5 years has promoted the discovery, optimization, characterization and development of engineered therapeutic antibodies. As part of the activities to respond to the COVID-19 health emergency, she led the development of the first diagnostic kit for the detection of anti-SARS-CoV2 antibodies, fully developed and manufactured in Mexico, which was authorized for commercialization by the Mexican Health Agency, COFEPRIS.

 

She currently participates as an expert member of the Committee of Biotechnological Products of the Mexican Pharmacopoeia (FEUM). She also is member of the Consortium of Innovator Scientists in Vaccines led by the Mexican Foreign Affairs Ministry, and technical responsible of various projects supported by CONACYT, including the National Laboratory of Specialized Services for Research, Development and Innovation (R+D+i) for Pharmochemicals and Biotechnologicals (LANSEIDI-FarBiotec) and the project for the establishment of biotechnological platforms for innovation and development of therapies against the tumor microenvironment in leukemia, under the strategic programs PRONAII.